Neurocrine Biosciences NASDAQ: NBIX expects continued growth from its largest medicine, INGREZZA, despite pricing pressure, while preparing for multiple clinical trial readouts in 2027, executives said at a Jefferies-hosted discussion.
Chief Executive Officer Kyle Gano said the company’s third-quarter sales were running at an annualized rate of about $4.5 billion. Neurocrine now has three commercial medicines, and approximately 30% of its revenue comes from products other than INGREZZA, he said.
Gano highlighted upcoming Phase 3 results for osavampator in major depressive disorder and direclidine in schizophrenia, describing the programs as potentially “trajectory-changing” for the company.
INGREZZA outlook and Medicare pricing
INGREZZA generated $800 million in third-quarter sales, up about 15% from a year earlier, with double-digit volume growth and record prescription levels, Gano said. The company raised its guidance for the second time, he added.
Gano said Neurocrine expects access to INGREZZA in 2027 and 2028 to remain similar to current levels, although maintaining that access will involve pricing concessions. He expects those concessions and a higher statutory rebate on Medicare Part D sales to be offset by double-digit volume growth, resulting in higher revenue in 2027 and a similar trajectory in 2028.
Chief Financial Officer Matt Abernethy said the company expects 2028 to bring a low-single-digit price decline. He also pointed to INGREZZA intellectual property extending to 2038.
The executives described 2029, when INGREZZA will face Medicare price negotiation, as manageable. Gano said the company’s small biotech exemption provides a negotiation range of 25% to 34% below a benchmark known as non-FAMP. Abernethy said the effect would be partly offset by factors including the end of a statutory rebate, but rejected the suggestion that there would be no pricing impact.
“We do see the 2029 window is definitely not falling off a patent event,” Abernethy said. He added that the company expects durable revenue growth after that period.
CRENESSITY and next-generation treatments
Gano said CRENESSITY, Neurocrine’s treatment for congenital adrenal hyperplasia, was running at an annualized sales rate of about $850 million. More than 15% of an estimated 20,000 patients with the condition were receiving the medicine, he said.
Asked about potential competition from Vertex, Gano said multiple companies in the market could help accelerate patient adoption. He expressed confidence in CRENESSITY’s long-term growth prospects, citing its effects on hormone levels and glucocorticoid use, as well as its pediatric data. Neurocrine also has an ongoing study that could support treatment of younger children, he said.
For tardive dyskinesia, the company is developing next-generation VMAT2 inhibitors, including NBI-’890. Chief Medical Officer Eiry Roberts said a Phase 2 dose-finding study for the oral medicine is expected to read out in mid-2027. Those results will inform work on a long-acting injectable formulation, which the company plans to develop on a staggered timeline after the oral version.
Depression trials expected in second half of 2027
Roberts said Neurocrine expects results from three Phase 3 studies of osavampator in the second half of 2027. Each study has approximately 200 patients, the same size as the Phase 2 trial. The company chose three studies rather than two to provide an additional opportunity for a positive result, she said.
Roberts said the company has sought to limit variability through trial design, investigator training and blinded reviews of data from study sites. It has stopped or retrained some sites based on those reviews, she said.
She also reported a low dropout rate in the short-term Phase 3 studies and said more than 90% of participants had rolled over into an open-label extension. Data safety monitoring board reviews had resulted in no program changes, Roberts said, while noting that the medicine still needs to perform in the trials.
About Neurocrine Biosciences (NASDAQ:NBIX)
Neurocrine Biosciences is a biopharmaceutical company focused on developing and commercializing treatments for neurological, endocrine and related disorders. Founded in 1992 and headquartered in San Diego, California, the company conducts research and development alongside its commercial operations. Its marketed medicines include INGREZZA (valbenazine), approved in the United States for tardive dyskinesia and chorea associated with Huntington disease, and CRENESSITY (crinecerfont), used with glucocorticoid replacement therapy to treat classic congenital adrenal hyperplasia in adults and children.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Neurocrine Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurocrine Biosciences wasn't on the list.
While Neurocrine Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.